Novo Outbid As Sanofi Agrees €3.9bn Ablynx Acquisition
Sanofi is to acquire Belgian nanobody developer Ablynx in an all-cash deal worth €3.9bn, 50% higher than the spurned bid by Novo Nordisk.
Sanofi is to acquire Belgian nanobody developer Ablynx in an all-cash deal worth €3.9bn, 50% higher than the spurned bid by Novo Nordisk.